---
schema_version: "secwatch.filing_event.v1"
accession: "0001860782-24-000074"
form_type: "8-K"
ticker: null
cik: "0001860782"
company_name: "2seventy bio, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T13:25:50.239407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 2seventy bio Q1 revenue $12.4M, net loss $52.7M; FDA approved Abecma for earlier line; cash runway beyond 2027

## Summary
- FDA approved Abecma for triple-class exposed R/R myeloma after 2+ prior lines; sLVV manufacturing approved.
- Completed R&D pipeline divestiture to Regeneron, streamlining to focus solely on Abecma commercialization.
- Total revenue $12.4M (down 70% YoY); net loss $52.7M vs $47M; collaborative arrangement loss $1.2M.
- Costs reduced: R&D $43.9M (down 36% YoY); SG&A $12.7M (down 39% YoY); restructuring charges $4.2M.
- Cash $181.4M; expect cash runway beyond 2027; anticipate Abecma return to growth in H2 2024.

## SEC filing metadata
- accession: 0001860782-24-000074
- form_type: 8-K
- cik: 0001860782
- company_name: 2seventy bio, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000074/0001860782-24-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000074/tvst-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860782-24-000074
- JSON: https://secwatch.observer/filing/0001860782-24-000074.json
- Plain text: https://secwatch.observer/filing/0001860782-24-000074.txt

## Key facts
- Earnings Releases
  2seventy bio, Inc. reported the first quarter ended March 31, 2024 results: revenue $12.4 million, net income $52.7 million.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $12.4 million
  - Net income: $52.7 million
  - Result: reported results
  source text: Total revenues were $12.4 million for the three months ended March 31, 2024, compared to $41.6 million for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000074/0001860782-24-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.